Low-dose aspirin therapy for cardiovascular prevention: Quantification and consequences of poor compliance or discontinuation

American Journal of Cardiovascular Drugs

Volumn 10, Issue 2, 2010, Pages 125-141

  Herlitz, Johan ^a   Tóth, Peter P ^b,c   Næsdal, Jørgen ^d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Sterling Rock Falls Clinic ^*  (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN;

BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG ELUTING STENT; DRUG WITHDRAWAL; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; RISK MANAGEMENT;

EID: 77950116519     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11318440-000000000-00000     Document Type: Review

References (92)

1. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 2004 Jan; 25 (2): 166-181
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan 12; 324 (7329): 71-86
3. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 513S-48S
4. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 234S-64S
5. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009 Mar 17; 150 (6): 396-404
6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994 Jan 8; 308 (6921): 81-106
7. Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007 May 9; 297 (18): 2018-2024
8. Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med 2006 Jan; 30 (1): 74-77
9. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007 Jul; 120 (7): 631-635
10. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin ''resistance'' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008 Jan 26; 336 (7637): 195-198
11. Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications. Cardiol Rev 2006 Jan-Feb; 14 (1): 18-25
12. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006 Nov; 27 (22): 2667-2674
13. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004 Jul 15; 117 (2): 73-81
14. Kulkarni SP, Alexander KP, Lytle B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006 Jan; 151 (1): 185-191
15. Sappok T, Faulstich A, Stuckert E, et al. Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke 2001 Aug; 32 (8): 1884-1889
16. Simpson E, Beck C, Richard H, et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003 Mar; 145 (3): 438-444
17. Sud A, Kline-Rogers EM, Eagle KA, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother 2005 Nov; 39 (11): 1792-1797
18. Wald DS, Morton G, Walker K, et al. Long-term continuation on cardiovascular drug treatment in patients with coronary heart disease. Ann Pharmacother 2007 Oct; 41 (10): 1644-1647
19. Bachman DS. Discontinuing chronic aspirin therapy: another risk factor for stroke? Ann Neurol 2002 Jan; 51 (1): 137-138
20. Collet JP, Himbet F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000 Nov-Dec; 76 (2-3): 257-258
21. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004 Oct 23-29; 364 (9444): 1519-1521
22. Mitchell SM, Sethia KK. Hazards of aspirin withdrawal before transurethral prostatectomy. BJU Int 1999 Sep; 84 (4): 530
23. Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005 Feb 1; 45 (3): 456-459
24. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006 Sep 25; 166 (17): 1842-1847
25. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidencebased secondary prevention therapies in coronary artery disease. Circulation 2006 Jan 17; 113 (2): 203-212
26. Carney RM, Freedland KE, Eisen SA, et al. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol 1995 Jan; 14 (1): 88-90
27. Carney RM, Freedland KE, Eisen SA, et al. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med 1998 Spring; 24 (1): 35-39
28. De Schryver EL, van Gijn J, Kappelle LJ, et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke. J Neurol 2005 Nov; 252 (11): 1316-1321
29. Silagy CA, McNeil JJ, Donnan GA, et al. The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly (Prevention with low-dose Aspirin of Cardiovascular disease in the Elderly). J Am Geriatr Soc 1994 Jun; 42 (6): 643-647
30. Hamann GF, Weimar C, Glahn J, et al. Adherence to secondary stroke prevention strategies: results from the German Stroke Data Bank. Cerebrovasc Dis 2003; 15 (4): 282-288
31. Komiya T, Kudo M, Urabe T, et al. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease: assessment by platelet aggregation testing. Stroke 1994 Dec; 25 (12): 2337-2342
32. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007 Aug 11; 370 (9586): 493-503
33. Morant SV, McMahon AD, Cleland JG, et al. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 2004 Feb; 57 (2): 188-198
34. Rieckmann N, Kronish IM, Haas D, et al. Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. Am Heart J 2006 Nov; 152 (5): 922-927
35. Waeber B, Leonetti G, Kolloch R, et al. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999 Jul; 17 (7): 1041-1045
36. Wang Y, Wu D, Ma R, et al. A survey on adherence to secondary ischemic stroke prevention. Neurol Res 2006 Jan; 28 (1): 16-20
37. Califf RM, DeLong ER, Ostbye T, et al. Underuse of aspirin in a referral population with documented coronary artery disease.AmJ Cardiol 2002 Mar 15; 89 (6): 653-661
38. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004 Oct 19; 110 (16): 2361-2367
39. Matsuzaki K, Matsui K, Haraguchi N, et al. Ischemic heart attacks following cessation of aspirin before coronary artery bypass surgery: a report of two cases. Ann Thorac Cardiovasc Surg 1999 Apr; 5 (2): 121-122
40. Newby LK, Bhapkar MV, White HD, et al. Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. J Thromb Thrombolysis 2003 Dec; 16 (3): 119-128
41. Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004 Apr 13; 62 (7): 1187-1189
42. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004 Feb; 147 (2): 293-300
43. Glynn RJ, Buring JE, Manson JE, et al. Adherence to aspirin in the prevention of myocardial infarction: The Physicians' Health Study. Arch Intern Med 1994 Dec 12-26; 154 (23): 2649-2657
44. Maulaz AB, Bezerra DC, Michel P, et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005 Aug; 62 (8): 1217-1220
45. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000 Nov 11; 321 (7270): 1183-1187
46. Serrano P, Lanas A, Arroyo MT, et al. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002 Nov; 16 (11): 1945-1953
47. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000 Sep; 95 (9): 2218-2224
48. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995 Apr 1; 310 (6983): 827-830
49. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004 Sep; 56 (3): 387-437
50. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008 Jul; 135 (1): 41-60
51. Norman M, Parker MJ. Compliance with a pharmacological secondary fracture prevention policy. Injury 2006 Aug; 37 (8): 718-720
52. ten Doesschate MC, Koeter MW, Bockting CL, et al. Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord 2010 Jan; 120 (1-3): 126-132
53. Adams AS, Trinacty CM, Zhang F, et al. Medication adherence and racial differences in A1C control. Diabetes Care 2008 May; 31 (5): 916-921
54. Walker EA, Molitch M, Kramer MK, et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 2006 Sep; 29 (9): 1997-2002
55. Bonolo P, César C, Acú rcio F, et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS 2005; 19 Suppl. 4: S5-13
56. Diaz-Fuentes G, Rodriguez J, Maluf C, et al. Improving compliance for prophylaxis of venous thromboembolism. Internet J Intern Med 2006; 6 (1)
57. Fredericks EM, Magee JC, Opipari-Arrigan L, et al. Adherence and healthrelated quality of life in adolescent liver transplant recipients. Pediatr Transplant 2008 May; 12 (3): 289-299
58. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and metaanalysis. J Intern Med 2005 May; 257 (5): 399-414
59. Beving H, Zhao C, Albage A, et al. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul Fibrinolysis 1996 Jan; 7 (1): 80-84
60. Mousa SA, Forsythe MS, Bozarth JM, et al. Effect of single oral dose of aspirin on human platelet functions and plasma plasminogen activator inhibitor-1. Cardiology 1993; 83 (5-6): 367-373
61. Coleman JL, Alberts MJ. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. Am J Cardiol 2006 Sep 15; 98 (6): 838-841
62. Serebruany VL, Malinin AI, Bhatt DL. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? Am J Med 2006 Aug; 119 (8): 707 e11-6
63. Chiang N, Bermudez EA, Ridker PM, et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A 2004 Oct 19; 101 (42): 15178-15183
64. Aguejouf O, Eizayaga F, Desplat V, et al. Prothrombotic and hemorrhagic effects of aspirin. Clin Appl Thromb Hemost 2009 Oct; 15 (5): 523-528
65. Kroenke K, Pinholt EM. Reducing polypharmacy in the elderly: a controlled trial of physician feedback. J Am Geriatr Soc 1990 Jan; 38 (1): 31-36
66. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 Nov 16; 348 (9038): 1329-1339
67. Laheij RJ, Jansen JB, Verbeek AL, et al. Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease. Aliment Pharmacol Ther 2001 Jul; 15 (7): 1055-1059
68. Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004 Jan 1; 159 (1): 23-31
69. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005 Nov 1; 22 (9): 795-801
70. Chisholm-Burns MA, Spivey CA. Pharmacoadherence: a new term for a significant problem. Am J Health Syst Pharm 2008 Apr 1; 65 (7): 661-667
71. Diaz-Fuentes G, Rodriguez J, Maluf C, et al. Improving compliance for prophylaxis of venous thromboembolism. Internet J Intern Med 2006; 6 (1)
72. Gallefoss F, Bakke PS. How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication? Am J Respir Crit Care Med 1999 Dec; 160 (6): 2000-2005
73. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch InternMed 2007 Mar 26; 167 (6): 540-550
74. van Dulmen S, Sluijs E, van Dijk L, et al. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res 2007; 7: 55
75. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl JMed 2005 Dec 1; 353 (22): 2373-2383
76. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007 Jan; 23 (1): 163-173
77. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008 Oct; 103 (10): 2465-2473
78. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008 Oct; 135 (4): 1383-1391, 91 e1-5
79. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008 Sep 16; 52 (12): 1038-9; author reply: 1039
80. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 Mar 31; 180 (7): 713-718
81. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl JMed 2009 Jan 22; 360 (4): 363-375
82. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, doubleblind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008 Jan 22; 51 (3): 256-260
83. Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study [abstract]. Circulation 2008; 118 (18): S815
84. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract]. Circulation 2008; 118 (18): S815
85. Zairis M, Patsourakos N, Makrygiannis S, et al. The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting [abstract]. Eur Heart J 2008; 29 Suppl.: 134
86. Ramirez JF, Selzer F, Chakaprani R, et al. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry [abstract]. J Am Coll Cardiol 2009; 53 (10 Suppl. 1): 2903
87. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a protonpump inhibitor: an analysis of two randomised trials. Lancet 2009 Sep 19; 374 (9694): 989-997
88. Muldowney J, Benge CD. Combination therapy with clopidogrel and protonpump inhibitors [letter]. Lancet 2010; 375: 27
89. Bhala N, Banerjee A. Combination therapy with clopidogrel and proton-pump inhibitors [letter]. Lancet 2010; 375 (9708): 28; author reply: 28-29
90. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000 Sep; 9 (9 Suppl.): 2-6
91. Sapienza S, Sacco P, Floyd K, et al. Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. Clin Ther 2003 Jun; 25 (6): 1872-1887
92. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007 Aug; 120 (8): 713-719